Bibiana Bielekova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2854686/publications.pdf

Version: 2024-02-01

91 papers	7,725 citations	81889 39 h-index	51602 86 g-index
103 all docs	103 docs citations	103 times ranked	8234 citing authors

#	Article	IF	Citations
1	Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. Journal of Immunotherapy, 2013, 36, 133-151.	2.4	953
2	Encephalitogenic potential of the myelin basic protein peptide (amino acids 83â€“99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nature Medicine, 2000, 6, 1167-1175.	30.7	783
3	Regulatory CD56^{bright}natural killer cells mediate immunomodulatory effects of IL-2RÎ±-targeted therapy (daclizumab) in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5941-5946.	7.1	588
4	Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon Î². Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8705-8708.	7.1	326
5	A role for interleukin-2 trans-presentation in dendritic cellâ€“mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine, 2011, 17, 604-609.	30.7	267
6	Development of biomarkers in multiple sclerosis. Brain, 2004, 127, 1463-1478.	7.6	266
7	Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nature Medicine, 1999, 5, 1375-1382.	30.7	216
8	Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis. Journal of Immunology, 2004, 172, 3893-3904.	0.8	208
9	Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Frontiers in Neurology, 2017, 8, 577.	2.4	197
10	Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Human Molecular Genetics, 2003, 12, 2191-2199.	2.9	191
11	Complex immunomodulatory effects of interferon-Î² in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Annals of Neurology, 2001, 50, 349-357.	5.3	171
12	Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis. Archives of Neurology, 2009, 66, 483-9.	4.5	159
13	Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain, 2015, 138, 3581-3597.	7.6	159
14	Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology, 2016, 3, 166-179.	3.7	142
15	Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple Sclerosis. Journal of Immunology, 2011, 187, 781-790.	0.8	138
16	Evolution of the bloodâ€“brain barrier in newly forming multiple sclerosis lesions. Annals of Neurology, 2011, 70, 22-29.	5.3	137
17	Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis. Science Translational Medicine, 2012, 4, 145ra106.	12.4	137
18	Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Annals of Neurology, 2015, 78, 3-20.	5.3	133

#	Article	IF	Citations
19	Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases. Journal of Immunology, 2014, 192, 2551-2563.	0.8	130
20	An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2â€"Driven Activation of CD56bright NK Cells. Journal of Immunology, 2010, 185, 1311-1320.	0.8	113
21	Monoclonal antibodies in MS. Neurology, 2010, 74, S31-40.	1.1	103
22	Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases. Journal of Immunology, 2000, 164, 1117-1124.	0.8	96
23	Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology, 2011, 77, 1877-1886.	1.1	91
24	Myelin-Associated Oligodendrocytic Basic Protein: Identification of an Encephalitogenic Epitope and Association with Multiple Sclerosis. Journal of Immunology, 2000, 164, 1103-1109.	0.8	82
25	Daclizumab Therapy for Multiple Sclerosis. Neurotherapeutics, 2013, 10, 55-67.	4.4	82
26	Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation. PLoS ONE, 2012, 7, e48370.	2.5	75
27	Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain, 2003, 126, 20-31.	7.6	74
28	Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7. Journal of Neuroimmunology, 1999, 100, 115-123.	2.3	70
29	VLA-4/CD49d downregulated on primed T lymphocytes during interferon-Î² therapy in multiple sclerosis. Journal of Neuroimmunology, 2000, 111, 186-194.	2.3	64
30	Human Autoreactive CD4+ T Cells from Naive CD45RA+ and Memory CD45RO+ Subsets Differ with Respect to Epitope Specificity and Functional Antigen Avidity. Journal of Immunology, 2000, 164, 5474-5481.	0.8	62
31	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. Journal of Autoimmunity, 2001, 16, 187-192.	6.5	61
32	Antigen-specific immunomodulation via altered peptide ligands. Journal of Molecular Medicine, 2001, 79, 552-565.	3.9	59
33	Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. Frontiers in Neurology, 2016, 7, 131.	2.4	59
34	Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e560.	6.0	54
35	Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 445-455.	3.7	53
36	The effects of interleukin-2 on immune response regulation. Mathematical Medicine and Biology, 2018, 35, 79-119.	1.2	51

#	Article	IF	Citations
37	Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Bloodâ€"Brain Barrier Function in Neonatalâ€Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatalâ€Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis and Rheumatology, 2017, 69, 1325-1336.	5.6	50
38	Molecularâ€based diagnosis of multiple sclerosis and its progressive stage. Annals of Neurology, 2017, 82, 795-812.	5.3	45
39	New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability. Frontiers in Neurology, 2017, 8, 598.	2.4	41
40	Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit bloodâ€"brain barrier disruption in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1206-1214.	3.0	40
41	Identifying and Quantifying Neurological Disability via Smartphone. Frontiers in Neurology, 2018, 9, 740.	2.4	39
42	A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis. PLoS ONE, 2014, 9, e105434.	2.5	36
43	Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology, 2016, 86, 847-855.	1.1	36
44	Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults. Clinical Infectious Diseases, 2017, 64, 275-283.	5.8	36
45	Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course. EBioMedicine, 2019, 43, 392-410.	6.1	36
46	Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity. Multiple Sclerosis and Related Disorders, 2019, 28, 34-43.	2.0	36
47	How Implementation of Systems Biology into Clinical Trials Accelerates Understanding of Diseases. Frontiers in Neurology, 2014, 5, 102.	2.4	35
48	NeurEx: digitalized neurological examination offers a novel highâ€resolution disability scale. Annals of Clinical and Translational Neurology, 2018, 5, 1241-1249.	3.7	33
49	Outcomes in Previously Healthy Cryptococcal Meningoencephalitis Patients Treated With Pulse Taper Corticosteroids for Post-infectious Inflammatory Syndrome. Clinical Infectious Diseases, 2021, 73, e2789-e2798.	5.8	33
50	Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clinical Proteomics, 2012, 9, 9.	2.1	32
51	Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis. Multiple Sclerosis Journal, 2014, 20, 156-164.	3.0	32
52	Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes. Annals of Clinical and Translational Neurology, 2015, 2, 1071-1084.	3.7	32
53	Genetic model of MS severity predicts future accumulation of disability. Annals of Human Genetics, 2020, 84, 1-10.	0.8	28
54	Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis. Npj Digital Medicine, 2021, 4, 36.	10.9	28

#	Article	IF	Citations
55	CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology, 2013, 80, 453-457.	1.1	26
56	Biomarkers in Multiple Sclerosis. Disease Markers, 2006, 22, 183-185.	1.3	25
57	The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 133-140.	2.0	25
58	Incomplete Susac syndrome exacerbated after natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e151.	6.0	25
59	Daclizumab Therapy for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034470.	6.2	25
60	Emerging Therapies for Multiple Sclerosis. Neurotherapeutics, 2007, 4, 676-692.	4.4	24
61	Novel composite MRI scale correlates highly with disability in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2015, 4, 526-535.	2.0	24
62	Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology, 2014, 82, 984-988.	1.1	22
63	Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 358.	2.4	21
64	Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731668893.	1.0	20
65	Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096901.	3.5	20
66	Idebenone does not inhibit disability progression in primary progressive MS. Multiple Sclerosis and Related Disorders, 2020, 45, 102434.	2.0	17
67	Neurofilament light chain levels correlate with clinical measures in CLN3 disease. Genetics in Medicine, 2021, 23, 751-757.	2.4	17
68	Prognostic value of serum/plasma neurofilament light chain for <scp>COVID</scp>â€•19â€•associated mortality. Annals of Clinical and Translational Neurology, 2022, 9, 622-632.	3.7	17
69	Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping. Seminars in Pediatric Neurology, 2017, 24, 229-239.	2.0	16
70	Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?. Neurology, 2015, 84, 1620-1621.	1.1	15
71	Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects. Frontiers in Neurology, 2018, 9, 554.	2.4	14
72	Pharmacodynamic effects of daclizumab in the intrathecal compartment. Annals of Clinical and Translational Neurology, 2017, 4, 478-490.	3.7	13

#	Article	IF	Citations
73	Central nervous systemâ€“restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation. Blood Advances, 2019, 3, 503-507.	5.2	13
74	National Institutes of Health Center for Human Immunology Conference, September 2009. Annals of the New York Academy of Sciences, 2010, 1200, E1-23.	3.8	12
75	Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e196.	6.0	12
76	Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 1241.	2.4	12
77	Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 1232.	2.4	12
78	Multiple sclerosis: Immunotherapy. Current Treatment Options in Neurology, 1999, 1, 201-219.	1.8	11
79	The effect of vesnarinone on TNFÎ± production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. Journal of Neuroimmunology, 1999, 97, 134-145.	2.3	11
80	Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity. Frontiers in Neuroscience, 2021, 15, 649876.	2.8	11
81	Assessment of Smartphone-Based Spiral Tracing in Multiple Sclerosis Reveals Intra-Individual Reproducibility as a Major Determinant of the Clinical Utility of the Digital Test. Frontiers in Medical Technology, 2021, 3, 714682.	2.5	7
82	Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	2.4	6
83	Evolution of tumefactive lesions in multiple sclerosis: A 12-year study with serial imaging in a single patient. Multiple Sclerosis Journal, 2013, 19, 1539-1543.	3.0	5
84	Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures. Journal of Inherited Metabolic Disease, 2021, 44, 1013-1020.	3.6	5
85	A173: Cerebrospinal Fluid Cytokines Correlate With Innate Immune Cells in Neonatal Onset Multisystem Inflammatory Disease (NOMID) Patients in Clinical Remission Treated With Anakinra. Arthritis and Rheumatology, 2014, 66, S226-S226.	5.6	4
86	Sustained reduction of MS disability. Neurology, 2016, 87, 1966-1967.	1.1	3
87	Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping. Frontiers in Neurology, 2020, 11, 565957.	2.4	3
88	Drug library screen identifies inhibitors of toxic astrogliosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103499.	2.0	3
89	The imperative to find the courage to redesign the biomedical research enterprise. F1000Research, 0, 10, 641.	1.6	1
90	Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.. Blood, 2009, 114, 1610-1610.	1.4	1

#	Article	IF	Citations
91	Comment on â€œInterleukin-2/Interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammationâ€• Annals of Neurology, 2012, 71, 149-149.	5.3	0